We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

93 hedge funds and large institutions have $487M invested in IGM Biosciences in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $15M | Put options by funds: $7.91M

74% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 19

29% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 21

7% more funds holding

Funds holding: 87 → 93 (+6)

2.34% more ownership

Funds ownership: 67.77% → 70.11% (+2.3%)

5% less capital invested

Capital invested by funds: $514M → $487M (-$26.9M)

Holders
93
Holders Change
+6
Holders Change %
+6.9%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
33
Reduced
19
Closed
21
Calls
$15M
Puts
$7.91M
Net Calls
+$7.11M
Net Calls Change
+$6.92M

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$9.31M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$7.73M
3
EC
EcoR1 Capital
California
+$5.56M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.72M
5
UBS AM
UBS AM
Illinois
+$3.72M

Top Sellers

Rank Fund Capital Flow
1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$27.4M
2
State Street
State Street
Massachusetts
-$10.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$2.33M
4
EGP
Entrust Global Partners
New York
-$1.94M
5
CAM
Cormorant Asset Management
Massachusetts
-$1.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Redmile Group
California
$89.1M – – –
BBA
2
Baker Bros. Advisors
New York
$84.4M – – –
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$60M -$2.33M -125,234 -5%
AG
4
Artal Group
Luxembourg
$53.5M +$9.31M +500,000 +33%
Alkeon Capital Management
5
Alkeon Capital Management
New York
$27.6M +$1.77M +95,000 +10%
Vanguard Group
6
Vanguard Group
Pennsylvania
$22.2M +$7.73M +415,028 +100%
BlackRock
7
BlackRock
New York
$18.6M +$333K +17,867 +3%
UBS AM
8
UBS AM
Illinois
$15M +$3.72M +200,032 +55%
Goldman Sachs
9
Goldman Sachs
New York
$11.4M +$455K +24,463 +6%
WP
10
Woodline Partners
California
$10.8M – – –
CAM
11
Cormorant Asset Management
Massachusetts
$10.8M -$1.82M -97,800 -20%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$10.3M +$4.72M +253,614 +192%
EC
13
EcoR1 Capital
California
$7.98M +$5.56M +298,597 New
Millennium Management
14
Millennium Management
New York
$5.92M +$1.07M +57,558 +35%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$5.73M +$1.29M +69,101 +48%
State Street
16
State Street
Massachusetts
$4.59M -$10.4M -560,138 -77%
Voloridge Investment Management
17
Voloridge Investment Management
Florida
$4.34M +$1.21M +65,015 +67%
SB
18
Samsara BioCapital
California
$4.13M +$2.88M +154,664 New
IM
19
Islet Management
New York
$3.52M +$2.45M +131,700 New
Charles Schwab
20
Charles Schwab
California
$2.74M +$847K +45,502 +80%
Morgan Stanley
21
Morgan Stanley
New York
$2.58M +$849K +45,611 +89%
FAM
22
Fred Alger Management
New York
$2.29M +$1.59M +85,609 New
Northern Trust
23
Northern Trust
Illinois
$2.26M +$133K +7,128 +9%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.72M +$963K +51,700 +414%
Marshall Wace
25
Marshall Wace
United Kingdom
$1.55M +$1.08M +58,056 New
1
2 3 4 5

IGMS Hedge Fund Activity: Q1 2022 in Review

93 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2022, worth a combined $487M — down 5.2% from $514M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new IGMS positions and 21 closed out — a net gain of 6 holders — while 33 added to existing stakes and 19 trimmed.

The largest buyer was Artal Group, adding an estimated $9.31M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $27.4M sold.

  • 93 institutional investors held IGM Biosciences (IGMS) as of Q1 2022, up from 87 in Q4 2021.
  • Funds reported $487M of IGM Biosciences stock for Q1 2022, down 5.2% quarter-over-quarter.
  • 27 funds opened new IGM Biosciences positions in Q1 2022 and 21 closed out, a net change of +6 holders.
  • The largest IGM Biosciences buyer in Q1 2022 was Artal Group, an estimated $9.31M added.
  • The largest IGM Biosciences seller in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $27.4M sold.

Based on aggregated 13F filings for Q1 2022.